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Purpose: The purpose of this study is to report the complication profile and safety evaluation 
of supraselective intra-arterial melphalan chemotherapy in children undergoing treatment with 
advanced retinoblastoma.
Methods: Twelve eyes of 10 children with advanced retinoblastoma (Reese-Ellsworth Group 
Vb or International Classification Group D) were treated with supraselective intra-ophthalmic 
artery infusion of melphalan. Eleven eyes of nine children had previously failed traditional 
management with systemic chemotherapy and laser ablation and underwent intra-ophthalmic 
artery infusion of melphalan as an alternative to enucleation. Serial ophthalmic examinations, 
retinal photography, and ultrasonographic imaging were used to evaluate treatment regime.
Results: Ophthalmic artery cannulation was successfully performed in 12 eyes of 10 patients 
(total 16 times). Striking regression of tumor, subretinal and vitreous seeds were seen early 
in each case. No severe systemic side effects occurred. Grade III neutropenia was seen in one 
patient. No transfusions were required. Three patients developed a vitreous hemorrhage obscuring 
tumor visualization. One patient developed periocular edema associated with inferior rectus 
muscle inflammation per orbital MRI. This same patient had scattered intraretinal hemorrhages 
and peripapillary cotton wool spots consistent with a Purtscher’s-like retinopathy that resolved 
spontaneously. At the 6-month follow-up examination, nine eyes had no evidence of tumor 
progression, whereas three eyes were enucleated for tumor progression. In each enucleated 
case, viable tumor was identified on histopathologic examination.
Conclusions: Ophthalmic intra-arterial infusion with melphalan is an excellent globe-conserving 
treatment option in advanced retinoblastoma cases with minimal systemic side effects. Local 
toxicities include microemboli to the retina and choroid (1/12, 8%), vitreous hemorrhage 
(3/12, 25%), and myositis (1/12, 8%). Enucleation remained a definitive treatment for tumor 
progression in 3 of 12 eyes in this small case series with limited follow-up. Further studies 
are necessary to establish the role of supraselective intra-arterial melphalan chemotherapy for 
children with retinoblastoma.
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Introduction
Retinoblastoma is the most common intraocular tumor in childhood, occurring in 
∼1 in 15,000 live births, with 300 newly diagnosed children each year in the United 
States.1,2 Historically, treatment for children with advanced retinoblastoma involved 
enucleation and external beam radiation therapy that has significant complications 
including midfacial disfigurement and secondary primary malignancies.3–5 For over a 
decade, treatment has been focused on globe-preserving techniques including systemic 
chemotherapy and a combination of focal consolidative therapy including brachyther-Clinical Ophthalmology 2010:5 submit your manuscript | www.dovepress.com
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apy, laser photocoagulation, cryotherapy, or thermotherapy. 
Although this treatment approach has resulted in significant 
improvement in survival rates, up to 99% in the developed 
world, systemic chemotherapy frequently leads to serious 
toxic side affects including myelosuppression, infection, and 
the need for blood transfusion in up to 75% of cases.6–8 As a 
result, newer treatment approaches have involved localized 
delivery of chemotherapy to minimize systemic side effects 
of chemotherapy and have included periocular injection of 
carboplatin and intra-ophthalmic artery infusion of the che-
motherapeutic drug melphalan.9,10 However, recently concerns 
have been raised regarding periocular carboplatin with reports 
of severe localized side effects, such as extraocular motility 
changes, optic nerve toxicity, and periorbital fat necrosis 
with enophthalmia.10–12 Intra-arterial injection of melphalan 
in retinoblastoma patients has been reported by Yamane et al, 
Abramson et al, and our group.13–17 Herein, we summarize the 
treatment of 12 eyes of 10 children with advanced intraocular 
retinoblastoma (Reese-Ellsworth Group Vb or International 
Classification Group D, who would generally undergo enucle-
ation) with intra-ophthalmic artery infusion of melphalan.
Materials and methods
Under general anesthesia, the femoral artery cannulation was 
performed with a sterile 21-gauge micropuncture. A heparin 
bolus (60 units/kg IV) was administered to anticoagulate 
the patient. Additional heparin boluses were given based on 
hourly measurement of activated clotting time (ACT) with a 
goal of ACT between 200 and 250 sec. Under fluoroscopic 
X-ray guidance, a 4-French (F) guide catheter was maneu-
vered over a wire through the aortic arch into the ipsilateral 
external and internal carotid arteries (ICA) through which 
digital subtracted angiography was performed to assess 
vascular supply to the orbit. A Marathon microcatheter 
(EV3, Irvine, CA, USA) was then advanced over a Mirage 
microguide wire (EV3, Irvine, CA, USA) and into the ostium 
of the ophthalmic artery where a selective ophthalmic artery 
angiography was performed. The desired dose of melphalan 
was diluted in 30 cc of normal saline and infused by pulse 
injection over 30 min. Ophthalmic artery and ipsilateral ICA 
angiography were repeated to rule out any inadvertent throm-
boembolic episodes. All patients tolerated the procedure.
Ophthalmic evaluations under anesthesia were per-
formed approximately every 4 weeks after intra-arterial 
chemotherapy was completed and consisted of external 
and anterior segment examination for any evidence of 
iris neovascularization, hyphema, or hypopyon, indirect 
ophthalmoscopy with 360° of scleral depression, Ret Cam 
digital fundus photography (Massie Industires, Dublin, CA, 
USA) documenting all lesions, and B-scan ultrasonography 
(10 MHz). Between evaluations under anesthesia, the pedi-
atric oncologist performed systemic evaluation including an 
interval history and complete blood counts.
Results
This report summarizes our initial experience with intra-
ophthalmic artery infusion of the chemotherapeutic agent 
melphalan in 12 eyes of 10 children, all diagnosed with 
Reese-Ellsworth Group Vb or International Classification 
Group D retinoblastoma (unilateral 6, bilateral 4) (Table 1). 
Nine patients were previously treated with systemic che-
motherapy in a combination with laser photocoagulation. 
Systemic chemotherapy included carboplatin, vincristine, 
etoposide, and/or cyclosporine for nine cycles except for one 
patient who received 11 cycles. At the subsequent exams and 
as tumor progression was noted, seven patients were treated 
with periocular injections of carboplatin and one patient 
in addition had external beam radiation. Only patient #10 
received intra-arterial melphalan and laser photocoagula-
tion as the primary treatment, while the other nine patients 
received intra-arterial melphalan and laser photocoagulation 
as salvage therapy in the setting of disease progression after 
systemic chemotherapy and focal therapy.
All attempts at supraselective intra-arterial drug delivery 
were successful. There were 16 separate infusions in 
10 patients. Eight patients had unilateral and two patients had 
bilateral infusions. Four patients received repeat melphalan 
infusion at higher doses due to initial incomplete tumor 
response. The mean follow-up was 5.5 months and the median 
was 5.0 months. At the 5-month follow-up examination, 
nine eyes had no evidence of tumor progression. Three eyes 
required enucleation. The indications for enucleation were 
vitreous hemorrhage obscuring visualization of tumor, peri-
papillary tumor with concern for optic nerve invasion, and 
continued tumor progression. In each enucleated case, viable 
tumor was identified on histopathologic examination. These 
findings have been described elsewhere.15
Overall, 76.5% of tumors responded to therapy avoiding 
enucleation. Of the responders, 54% responded to single dose 
of melphalan. Representative cases before and after treatment 
are illustrated (Figures 1–3).
There were no severe systemic complications including 
fevers, infections, red blood cell or platelet transfusions, 
stroke or death. Grade III neutropenia was seen in one patient 
at 1 week. Scrotal hematoma at the femoral artery puncture 
site was noted in patient #9. Vitreous hemorrhage was Clinical Ophthalmology 2010:5 submit your manuscript | www.dovepress.com
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noted in three eyes on initial follow-up after intra-arterial 
melphalan infusion and was self-limiting in cases #4 and #5. 
Patient #10 developed periocular swelling, and an MRI of 
orbits showed inferior rectus muscle inflammation. Dilated 
funduscopic examination showed Purtscher’s-like retin-
opathy with peripapillary cotton wool spots and scattered 
intraretinal hemorrhages in the treated eye most likely due 
to an embolic event. These findings resolved spontaneously 
on close follow-up (Figure 3).
Discussion
This report describes our experiences with supraselective 
ophthalmic artery infusion with chemotherapy for patients 
with advanced intraocular retinoblastoma unresponsive to 
systemic chemotherapy and focal treatment.
Recently, local treatments including periocular adminis-
tration of carboplatin, and intra-arterial infusion of melphalan 
have been suggested as alternative modalities to systemic 
chemotherapy, especially in eyes with advanced disease 
(Reese-Ellsworth Group IV and V or International Classifi-
cation Group D). Responses have been demonstrated with 
periocular carboplatin; however, severe local side effects 
have been reported including extraocular motility changes, 
optic nerve toxicity (necrosis/atrophy), and periorbital fat 
necrosis.10–12 Intra-arterial infusion of melphalan has been 
reported, as noted, in a small case series by Abramson et al.14 
In Japan, clinicians have been investigating intracarotid 
infusion of chemotherapy for the past 15 years. They have 
successfully infused melphalan into the cervical ICA while 
occluding the distal internal carotid just past ophthalmic 
artery bifurcation in 97.5% of 563 treatments.13 Many of 
these eyes also received external beam radiation therapy and 
intravitreal melphalan making it difficult to draw efficacy 
conclusions. In the United States, Abramson and associates 
reported good outcomes after selective intra-ophthalmic 
artery infusion of melphalan in a phase I/II clinical trial. They 
enrolled 10 patients and were able to successfully cannulate 
ophthalmic artery in nine patients. Of these treated patients, 
eight had visual stabilization or improvement. All patients 
had poor electroretinogram profiles at baseline, and these 
were unchanged after treatment. Enucleation was avoided in 
seven patients. No severe local or systemic side effects were 
reported in this trial.14,18
At our institution, we have treated 12 eyes of 10 patients 
with selective intra-arterial melphalan at varying doses. 
All cases had advanced retinoblastoma Reese-Ellsworth 
Group Vb or International Classification Group D, and all 
but one patient had received and failed multiagent chemore-Clinical Ophthalmology 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
174
Vajzovic et al
duction therapy combined with laser photocoagulation. In 
addition, one patient was treated with external beam radia-
tion without success. In 11 eyes, the decision was made to 
proceed with intra-arterial melphalan combined with focal 
laser   photocoagulation as a salvage treatment option before 
Figure 2 Patient #1 presented with reese-ellsworth Group Vb or international 
Classification Group D retinoblastoma initially treated with systemic multiagent 
chemoreduction (carboplatin, vincristine, etoposide, and cyclosporine) with focal 
laser photocoagulation and subsequently with six periocular carboplatin injections. 
even with this aggressive treatment, the tumor continued to progress. The patient 
then underwent intra-arterial melphalan infusion as salvage therapy at the 3-mg 
dose and then at the 7.5-mg dose. subsequently, the patient developed a vitreous 
hemorrhage obscuring tumor visualization. echographic evaluation demonstrated 
tumor progression, and the patient underwent definitive therapy with enucleation. 
A) At presentation. B) Before first melphalan infusion (3-mg dose). C) Before 
second melphalan infusion (7.5 mg).
A
B
C
Figure 1 Patient #8 diagnosed with unilateral advanced reese-ellsworth Group 
Vb  or  International  Classification  Group  D  retinoblastoma  previously  treated 
with systemic chemoreduction and focal consolidative treatment, then periocular 
carboplatin injections without tumor regression. As a salvage therapy, intra-arterial 
melphalan infusion at 5 mg was performed, which lead to tumor regression. A) At 
presentation. B) After systemic chemoreduction and focal laser photocoagulation. 
C) Five months after a single infusion of melphalan at 5-mg dose.
A
B
C
standard   enucleation. At a 3–4 week follow-up interval 
after intra-  arterial melphalan treatment, a marked response 
with regression of retinal tumor, subretinal/vitreous seeds 
was noted in all patients. One eye in our series was treated 
with intra-arterial melphalan as a primary treatment Clinical Ophthalmology 2010:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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modality   combined with laser photocoagulation with the 
goal of avoiding long-term systemic chemotherapy and its 
associated morbidity. In this case, intra-arterial melphalan 
treatment resulted in complete resolution of the tumor by 
1 month posttreatment and no evidence of progression 
at 5 months (Figure 3). To date, 3 of the 12 eyes (25%) 
treated with intra-arterial melphalan have been   enucleated 
for   suspected tumor recurrence. These were eyes that 
previously had undergone extended chemoreduction, laser 
photocoagulation, and periocular carboplatin injections. 
On histopathologic examination of enucleated eyes, viable 
tumor was noted in all three cases.15
Although intra-arterial infusion of melphalan has shown 
promising results, we have noted several local side effects. 
These side effects included vitreous hemorrhage in three 
patients and Purtscher’s-like retinopathy secondary to an 
embolic event as well as inferior rectus inflammation in 
another patient. In two of three patients, vitreous hemorrhage 
was self-limited, and tumor regression was achieved. The 
third patient with vitreous hemorrhage underwent enucle-
ation for tumor progression. The Purtscher’s-like retinopathy 
  findings in the latter patient resolved spontaneously, and com-
plete tumor regression was noted at last follow-up. No severe 
systemic complications were identified during posttreatment 
period including fever, nausea, vomiting, alopecia, bone 
marrow suppression, sepsis, or any other condition requiring 
hospitalization.
In our experience, intra-arterial infusion of melphalan 
has been successful in achieving effective tumor reduction 
in advanced retinoblastoma cases primarily as globe-salvage 
therapy after failure of systemic chemotherapy combined with 
focal therapy. This alternative globe-preserving treatment has 
dramatically decreased enucleation rate at our institution. It 
should be noted that this approach requires consolidation with 
focal therapy, such as laser, after completion of intra-arterial 
chemotherapy. Clinicians offering this treatment modality 
should be aware of short-term potential local adverse effects, 
such as vitreous hemorrhage and Purtsher’s-like retinopathy as 
well as lack of tumor response. Larger patient series are needed 
to establish the role of supraselective intra-arterial melphalan 
chemotherapy for children with retinoblastoma. Collaborative 
series among large institutions are currently in development 
with the Children’s Oncology Group and these series will 
greatly advance the rate at which we can learn more about this 
exciting therapy since   retinoblastoma is a rare disease.
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